UBS maintains 'Sell' on Fresenius Medical Care, DZ Bank cuts fair value to 46 euros on US dialysis reform risk

Following US government reform plans for the dialysis market, UBS maintained a 'Sell' rating on Fresenius Medical Care, citing the proposals as a significant new risk. DZ Bank lowered its fair value estimate from 54 to 46 euros while keeping a 'Buy' rating, noting reforms could introduce new market hurdles and impact cost reimbursement structures.

Detected & updated continuously · Source: Nebula